CA
RYTM icon

Clearstead Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Clearstead Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$779 Buy
+7
New +$633 ﹤0.01% 2783
2026
Q1 		– Sell
-1,246
Closed -$133K – 2754
2025
Q4 		$133K Buy
1,246
+847
+212% +$89.8K ﹤0.01% 1037
2025
Q3 		$40.3K Sell
399
-191
-32% -$17.7K ﹤0.01% 1349
2025
Q2 		$37.3K Buy
+590
New +$36.1K ﹤0.01% 1386

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Clearstead Advisors's RYTM Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 7 shares worth $779. The stake represents ﹤0.01% of the portfolio and ranks #2783 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in RYTM as recently as Q4 2025.

Clearstead Advisors first reported a position in RYTM in Q2 2025 and has held it in 4 quarters since. The position peaked at $133K in Q4 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Clearstead Advisors held 7 shares of Rhythm Pharmaceuticals worth $779 as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2783 holding.
  • Clearstead Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Rhythm Pharmaceuticals position peaked at $133K in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.